Arkema SA (OTCMKTS:ARKAY) Receives Consensus Recommendation of “Reduce” from Analysts

Arkema SA (OTCMKTS:ARKAY) has been given an average recommendation of “Reduce” by the seven research firms that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and two have given a buy recommendation to the company.

ARKAY has been the topic of several recent research reports. Barclays cut shares of Arkema from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 11th. Zacks Research lowered Arkema from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft cut Arkema from a “buy” rating to a “hold” rating in a research report on Monday, November 24th. Finally, The Goldman Sachs Group raised Arkema from a “hold” rating to a “buy” rating in a research report on Tuesday, February 10th.

Arkema Stock Up 0.9%

Shares of OTCMKTS ARKAY opened at $71.29 on Monday. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.07 and a quick ratio of 2.26. The company has a 50-day moving average price of $63.90 and a 200-day moving average price of $63.94. The stock has a market capitalization of $5.42 billion, a P/E ratio of 34.28, a P/E/G ratio of 1.45 and a beta of 0.90. Arkema has a 1 year low of $56.28 and a 1 year high of $91.51.

Arkema Company Profile

Arkema SA is a global specialty chemicals and advanced materials company headquartered in Colombes, France. Established in 2004 as a spin-off from Total’s chemicals division, the company offers a broad portfolio of high-performance materials designed to improve durability, thermal and chemical resistance, and environmental performance across diverse industries.

Arkema’s operations are organized into four core segments. Adhesive Solutions delivers bonding, sealing, and coating technologies for markets such as packaging, medical devices, and consumer goods.